Drugs Approved for Myeloproliferative Neoplasms or Myelodysplastic Syndromes
- Adriamycin PFS (Doxorubicin Hydrochloride)
- Adriamycin RDF (Doxorubicin Hydrochloride)
- Arsenic Trioxide
- Azacitidine
- Besremi (Ropeginterferon Alfa-2b-njft)
- Cerubidine (Daunorubicin Hydrochloride)
- Clafen (Cyclophosphamide)
- Cyclophosphamide
- Cytarabine
- Cytosar-U (Cytarabine)
- Cytoxan (Cyclophosphamide)
- Dacogen (Decitabine)
- Dasatinib
- Daunorubicin Hydrochloride
- Decitabine
- Decitabine and Cedazuridine
- Doxorubicin Hydrochloride
- Fedratinib Hydrochloride
- Gleevec (Imatinib Mesylate)
- Grafapex (Treosulfan)
- Imatinib Mesylate
- Imkeldi (Imatinib Mesylate)
- Imetelstat Sodium
- Inqovi (Decitabine and Cedazuridine)
- Inrebic (Fedratinib Hydrochloride)
- Ivosidenib
- Jakafi (Ruxolitinib Phosphate)
- Nilotinib
- Pacritinib Citrate
- Pemazyre (Pemigatinib)
- Pemigatinib
- Ropeginteferon Alfa-2b-njft
- Rubidomycin (Daunorubicin Hydrochloride)
- Ruxolitinib Phosphate
- Rytelo (Imetelstat Sodium)
- Sprycel (Dasatinib)
- Tarabine PFS (Cytarabine)
- Tasigna (Nilotinib)
- Tibsovo (Ivosidenib)
- Treosulfan
- Trisenox (Arsenic Trioxide)
- Vidaza (Azacitidine)
- Vonjo (Pacritinib Citrate)
Drug Combinations Used in Myeloproliferative Neoplasms or Myelodysplastic Syndromes